Two billion tablets
“This comprises the largest single investment in the history of Merck Spittal“, says Klaus Raunegger, Managing Director of Merck in Spittal. The site has long become a showcase plant within the Merck Group of Germany. Four of the company’s eight most important brands on the global market are manufactured in Carinthia. “Over the last ten years the number of packs of medicine produced here has increased five-fold, from 14 million to 70 million. The volume of tablets manufactured in Spittal has climbed from 400 million to 1.3 billion”, Raunegger explains. More than 90 percent of the medication is destined for export. In 2018, the “competence center” in Spittal is expected to manufacture about two billion tablets annually. The plant produces, amongst other products, various over the counter vitamin products and food supplements, nose sprays (Nasivin) and pain relief creams. The production of “Vigantoletten” (Vitamin D) is being transferred from Darmstadt to Spittal within the context of the expansion program. Quality control also takes place at the Carinthian facility. Production volume has risen four-fold overall during the last ten years.